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Abstract
Background: Tumor suppressor gene p53 plays an important role in the maintenance of the genomic integrity,
and mutation in the gene may alter an individual’s susceptibility to various carcinomas. P53 Arg72Pro or codon 72
polymorphism has been indicated to increase the risk of developing certain cancers such as bladder cancer and
cervical cancer. Human papillomavirus (HPV) infection has been shown as a risk factor for certain cancers such as
cervical cancer and oral cancer as well, and the HPV oncoprotein E6 may induce the degradation of p53 function.
However, the association between p53 Arg72Pro polymorphism and the risk of oral cancer with HPV infection remains
inconclusive. Therefore, this meta-analysis involving 5,614 participants was performed to investigate the relations
among the p53 Arg72Pro polymorphism, HPV infection, and the risk of developing oral cancer.
Results: A search of the literature by PubMed, Embase, Web of Science, and China National Knowledge Infrastructure
databases was conducted to identify studies based on the inclusion and exclusion criteria. Odds ratios with 95 %
confidence intervals were combined using a random-effect model or a fixed-effect model. The current study was
conducted with 13 studies consisting of 2,413 cases and 3,201 controls. Neither overall analysis nor stratified analyses
detected any obvious evidence of association between p53 Arg72Pro polymorphism and oral cancer susceptibility in
all genetic models. However, a significant association between p53 Arg72Pro polymorphism and the risk of oral cancer
with HPV infection was detected in the Arg/Arg vs. Arg/Pro + Pro/Pro model.
Conclusion: In the current meta-analysis which used the quantitative data synthesis for the first time, our
study demonstrated that p53 Arg72Pro polymorphism together with HPV infection might jointly alter an individual’s
susceptibility to the risk of oral cancer. Our results suggested that p53 Arg72Pro polymorphism may partly contribute
to the pathogenesis of oral cancer development.
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Background
The incident rate for oral cancer has been increasing re-
cently. Research studies have suggested that smoking,
alcohol consumption, and betel quid chewing are risk
factors that predispose individuals to oral cancer [1–3].
Nevertheless, only some smokers, alcohol users, and
betel quid users develop oral cancer, which indicated
that it can be a multifactorial process associated with
various risk factors for oral cancer development. These
exogenous carcinogens may induce a defective DNA
damage response, which may alter the expression of
tumor suppressor genes apoptosis or may result in gen-
omic instability [4, 5]. Accumulative evidence indicates
that individual susceptibility to oral cancer also depends
on genetic predisposition and viral infection [6, 7].
Therefore, both environmental and genetic factors may
play an important role in the process of oral cancer
development.
Many published studies have reported that oral carcin-
oma susceptibility is associated with gene polymorphism.
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In recent years, much attention has been focused on the
p53 codon 72 Arg/Pro polymorphism. The p53 tumor
suppressor gene is located at human chromosome 17
and encoding a 53-kDa nuclear phosphoprotein which
plays a crucial role in cell cycle regulation, maintenance
of genomic integrity, apoptosis, and challenge of envir-
onmental insults [8, 9]. Mutant p53 codon 72 may allow
cells with environment-associated damaged DNA to
enter the cell cycle, leading to the development of tu-
mors [10, 11]. In fact, there have been extensive research
studies demonstrated that p53 Arg72Pro polymorphism
played an important role in developing cervical cancer
in HPV-positive patients. Odds of developing cervical
cancer was significantly higher with the p53 Arg allele in
HPV associated cervical cancer. This association was not
detected in HPV-negative patients [12]. In addition, the
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Fig. 1 Flow diagram of the publication selection process
Table 1 Main characteristics of studies included in the meta-analysis
Study Country Ethnicity Control source Genotyping Methods Sample size (case/control)
Patel KR et al. [28] India Asian healthy PCR-RFLP 79/110
Wang Z et al. [18] USA Caucasian healthy PCR-RFLP 320/321
Ji X et al. [19] USA Caucasian healthy PCR-RFLP 188/342
Kuroda Y et al. [29] Japanese Asian Hospital PCR-RFLP 100/271
Kitkumthorn N et al. [30] Thailand Asian healthy PCR-RFLP 78/94
Chen X et al. [31] USA Caucasian healthy PCR-RFLP 326/349
Zemleduch T et al. [32] Caucasian Caucasian healthy PCR-RFLP 123/300
Ihsan R et al. [33] India Asian healthy PCR-RFLP 116/278
Tu HF et al. [34] Taiwan Asian healthy DNA sequence 189/116
Summersgill KF et al. [20] USA Caucasian Hospital PCR-CTPP 190/308
Misra C et al. [35] India Asian Hospital PCR-RFLP 308/342
Lin YC et al. [36] Taiwan Asian unknown PCR-RFLP 297/280
Saini R et al. [37] Malaysia Asian healthy PCR-CTPP 99/90
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Table 2 Distribution of p53 codon 72 genotypes among oral cancer in cases and controls
Cases (n) Controls (n)
First author Arg/Arg Arg/Pro Pro/Pro Arg/Arg Arg/Pro Pro/Pro P-value of HWE in controls
Patel KR et al. [28] 32 29 18 30 58 22 0.528
Wang Z et al. [18] 43 41 15 24 15 2 0.860
Ji X et al. [19] 103 74 11 179 140 23 0.532
Kuroda Y et al. [29] 41 44 15 109 117 45 0.159
Kitkumthorn N et al. [30] 35 40 3 27 47 20 0.957
Chen X et al. [31] 183 121 22 181 144 24 0.518
Zemleduch T et al. [32] 55 52 16 176 104 20 0.389
Ihsan R et al. [33] 30 63 23 63 143 72 0.619
Tu HF et al. [34] 53 106 30 41 60 15 0.337
Summersgill KF et al. [20] 102 70 18 168 112 28 0.144
Misra C et al. [35] 87 155 66 85 159 98 0.203
Lin YC et al. [36] 96 155 46 72 152 56 0.135
Saini R et al. [37] 22 40 37 28 39 23 0.215
HWE: Hardy–Weinberg equilibrium
Fig. 2 The association between p53 Arg72Pro polymorphism and the risk of oral cancer in total population (Arg72 allele vs. Pro72 allele)
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association between p53 Arg72Pro polymorphism and
oral cancer has been investigated, however, the results
were inconsistent.
HPV infection have been proved as an independent
risk factor for the development of oral cancer [13, 14].
The viral E6 protein, which encoded by two high risk
HPV types named HPV-16 and HPV-18, was testified to
bind and inactivate the human p53 gene product, and
marking it for destruction by the ubiquitin proteasome
pathway [15–17]. Storey et al. suggested that the p53
Arg72Pro polymorphism plays a part in the development
of HPV-associated cancer in 1998 for the first time [18].
Since then, researchers have investigated the combined
influence of the Arg72Pro polymorphism and HPV in-
fection in the risk of developing oral cancer, but the re-
sults remained inconclusive [19–21].
Therefore, whether or not p53 Arg72Pro polymorphism
can increase the risk of oral cancer with HPV infection re-
mains unclear. Based on the above reasons, we conducted
this evidence-based quantitative meta-analysis to investi-
gate the relationship between p53 polymorphisms and the
risk of HPV-related oral cancer.
Methods
Search strategy
Relevant articles were searched using combinations of
search terms “oral”, “oral cavity”, “buccal”, “oropharynx”,
“oral cancer”, “oral carcinoma”, “oral squamous cell
carcinoma”, “ameloblastoma”, “P53”, “TP53”, “Arg72Pro”,
“HPV”, “human papillomavirus”, “polymorphism”, “sus-
ceptibility”, and “gene variants”, in PubMed, Embase, Web
of Science, and China National Knowledge Infrastructure
databases, focusing on articles which were published from
their earliest entry points to April 2014.
Inclusion and exclusion criteria
The following inclusion criteria were used for the se-
lection of literature for meta-analysis: (1) published in
English; (2) examined case–control studies investigat-
ing the association between HPV infection, Arg72Pro
polymorphism, and the risk of oral cancer; (3) definite
histopathologic diagnosis; and (4) genotype distribution in
controls must be in Hardy-Weinberg equilibrium (HWE).
Major exclusion criteria included: (1) the unpublished re-
ports and abstracts; (2) when duplicated studies published
Fig. 3 The association between p53 Arg72Pro polymorphism and the risk of oral cancer in total population (Arg/Arg vs. Pro/Pro)
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by the same author, only the most recent publication
study was chosen.
Data extraction
All the eligible articles were independently reviewed and
extracted by two reviewers (YL and WY) according to
the selection criteria listed above. Disagreement was re-
solved by the third independent investigator (JH). The
following data were extracted from the each study: the
first author, year of publication, country, ethnicity, geno-
typing methods, source of the controls, and genotype
numbers from the cases and controls.
Statistical analysis
The STATA version 11.0 software (Stata Corporation,
College Station, TX) was used to conduct the statis-
tical analyses. The combined odds ratio (OR) with a
corresponding 95 % confidence interval (CI) was estimated
to evaluate the relationship among p53 Arg72Pro polymor-
phisms, HPV infection, and the risk of oral cancer. For
control groups, the goodness-of-fit test (Chi-square test or
Fisher exact test) was used to test the deviations from
HWE. The following statistical models were used in the
meta-analysis: the allelic model (Arg72 allele vs. Pro72
allele), the codominant model (homozygote comparison:
Arg/Arg vs. Pro/Pro), the dominant model (Arg/Arg +
Arg/Pro vs. Pro/Pro), and the recessive model (Arg/Arg vs.
Arg/Pro + Pro/Pro). Statistics Q and I2 statistic were
evaluated to investigate the between-study heterogen-
eity [22, 23]. Either the random-effect model or the
fixed-effect model was used to calculate the pooled
effect estimate either in the presence or in the ab-
sence of heterogeneity, respectively [24, 25]. Addition-
ally, the Begg’s funnel plot and the Egger’s test were
used to estimate the publication bias (p < 0.05 was
considered statistically significant) [26, 27].
Results
Studies characteristics
As shown in Fig. 1, 13 studies with a total of 5,614
participants met the inclusion and exclusion criteria
[19–21, 28–37]. The characteristics of these included
Fig. 4 The association between p53 Arg72Pro polymorphism and the risk of oral cancer in total population (Arg/Arg + Arg/Pro)
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articles were summarized in Table 1. All the related
distribution of p53 codon 72 polymorphism genotype
frequencies in cases and controls were summarized in
Table 2.
Meta-analysis results
The association between p53 Arg72Pro polymorphism and
the risk of oral cancer in total population
A total of 13 studies were included in the meta-analysis
to examine the association between p53 Arg72Pro poly-
morphism and the risk of oral cancer. There was no
evidence of a significant association in any genetic
model (Arg72 allele vs. Pro72 allele: OR = 1.05, 95 % CI:
0.90- 1.23; Arg/Arg vs. Pro/Pro: OR = 1.11, 95 % CI:
0.81- 1.52; Pro/Pro vs. Arg/Arg + Arg/Pro: OR = 0.94,
95 % CI: 0.72- 1.21; Arg/Arg vs. Arg/Pro + Pro/Pro:
OR = 1.07, 95 % CI: 0.91- 1.26; all p values >0.05;
Figs. 2, 3, 4 and 5, Table 3). However, significant het-
erogeneity across the studies was present in four gen-
etic models (P = 0.000, 0.002, 0.013, 0.023 for the
allelic genetic model, the homozygote comparison
model, the dominant model and the recessive model,
respectively Table 3).
The association between p53 Arg72Pro polymorphism and
the risk of oral cancer in a specific population
In order to determine the major cause for the heterogen-
eity, a stratified analysis of the specific populations was
performed. Eight studies were conducted in Asian popu-
lations and five studies were conducted in Caucasian
populations. No significant association between the risk
of oral cancer and p53 codon 72 polymorphism was de-
tected in the Asian and the Caucasian groups in any
genetic model (Table 3). Significant heterogeneity was
detected in both groups in all genetic models, except for
Pro/Pro vs. Arg/Arg + Arg/Pro in the Caucasian group
(Table 3).
The association between combined effect of p53 Arg72Pro
polymorphism with HPV infection and the risk of oral
cancer in total population
A total of five studies, including 396 cases and 213 con-
trols, were included to evaluate the relations among
HPV, p53 Arg72Pro polymorphism, and oral cancer sus-
ceptibility. The result showed that the association of
HPV with p53 Arg72Pro variant genotypes displayed a
statistical significance on oral cancer risk in the Arg/Arg
Fig. 5 The association between p53 Arg72Pro polymorphism and the risk of oral cancer in total population (Arg/Arg vs. Arg/Pro + Pro/Pro)
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vs. Pro carriers (Arg/Pro + Pro/Pro) model (OR: 0.68,
95 % CI: 0.48- 0.96, p = 0.028) (Fig. 2, Table 3). There
was no significant heterogeneity among these studies
(Q = 0.93, I2 = 0.0 %, P = 0.92; Table 3).
Publication bias
Begg’s funnel plots seemed to be approximately symmet-
rical in all meta-analyses (data not shown). Additionally,
Egger’s tests did not reveal any obvious evidence of pub-
lication bias either (Table 3).
Discussion
Since the identification of the p53 codon 72 polymorphism,
many studies have been devoted to explore the genetic
effect of p53 Arg72Pro polymorphism on susceptibility of
oral cancer. However, the evidence regarding the role of
single nucleotide polymorphism of p53 Arg72Pro gene as a
genetic marker for the risk of oral cancer is inconsistent.
This prompted us to undertake the present meta-analysis
to explore a more robust estimate of the relationship
between p53 Arg72Pro genetic variant and the oral cancer
susceptibility. In this study, we found that individuals who
have genetic variants (Arg/Pro genotype or Pro/Pro geno-
type) may not have induced modification of oral cancer
risk compared with those who carry wild-type genotype
(Arg/Arg genotype). Same SNP may play different roles in
the development of cancer in different ethnic populations.
Therefore, the relation of p53 Arg72Pro polymorphism
with oral cancer susceptibility might be affected by the
different ethnic groups. Nevertheless, neither Arg/Arg
genotype individuals nor Pro carriers have a significant as-
sociation with oral carcinoma in the Asian group or the
Caucasian group.
HPV belongs to a large virus family, the PAPOVA
virus family. There are nearly a hundred types of HPV
discovered in human [38]. In this family, some of the
members are known to be high-risk oncogenic HPV
type, such as HPV-16, HPV-18, HPV-33, and HPV-58.
Through encoding oncogenic protein E6, high-risk HPV
types inhibit p53 cell cycle tumor suppressor. The viral
E6 protein has a powerful binding affinity for p53 pro-
tein resulting in its ubiquitination and destruction,
thereby inducing degradation of p53 function and cell
cycle out of control [15]. Therefore, p53 gene may have
some interaction with HPV infection in susceptibility to
HPV-associated oral cancer. Some investigators have
found that joint action of the p53 codon 72 polymorph-
ism with HPV is associated with the risk of oral cancer
Table 3 Association, test heterogeneity and publication bias for p53 Arg72Pro polymorphism and the risk of oral cancer
Comparison Number of studies Sample size
(case/control)
Test of association Test of heterogeneity Publication bias
OR 95 %CI P value Model Q P value I2 P value (Begg’s) P value (Egger’s)
Arg72 allele vs.
Pro72 allele
Total 12 2,093/2,880 1.054 0.905-1.228 0.500 R 33.16 0.000 66.8 % 0.300 0.202
Caucasian 4 827/1,299 0.933 0.722-1.206 0.597 R 9.92 0.019 69.7 % 0.221 0.175
Asian 8 1,266/1,581 1.128 0.934-1.362 0.210 R 19.40 0.007 63.9 % 0.902 0.717
Arg/Arg vs.
Pro/Pro
Total 12 2,093/2,880 1.109 0.807-1.524 0.523 R 29.39 0.002 62.6 % 0.360 0.415
Caucasian 4 827/1,299 0.870 0.621-1.218 0.416 F 6.04 0.110 50.3 % 0.462 0.312
Asian 8 1,266/1,581 1.277 0.860-1.898 0.226 R 19.36 0.007 63.8 % 0.536 0.914
Arg/Arg + Arg/
Pro vs. Pro/Pro
Total 12 2,093/2,880 0.936 0.723-1.211 0.613 R 23.90 0.013 54.0 % 0.161 0.423
Caucasian 4 827/1,299 1.142 0.823-1.583 0.427 F 3.81 0.283 21.2 % 0.806 0.451




Total 13 2,413/3,201 1.069 0.907-1.259 0.426 R 23.56 0.023 49.1 % 0.511 0.302
Caucasian 5 1,147/1,620 0.975 0.777-1.224 0.828 R 8.54 0.074 53.2 % 0.060 0.054
Asian 8 1,266/1,581 1.161 0.917-1.471 0.215 R 13.19 0.068 46.9 % 0.902 0.883
HPV infection 5 396/213 0.677 0.478-0.959 0.027 F 0.93 0.920 0.0 % 0.462 0.400
Model Abbreviations: R = random-effect; F = fixed-effect
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[19, 20, 30], but different conclusions were obtained by
other investigators [21, 36]. Considering the above men-
tioned conflicting conclusions, a subgroup analysis of
interaction of p53 gene polymorphism with HPV infec-
tion on oral cancer susceptibility was performed. Our
study demonstrated a significant interaction between
HPV infection and p53 Arg72Pro polymorphism on the
risk of developing oral cancer in p53 Arg/Arg genotype
carriers compared with p53 72Pro carriers.
The small sample size is a major limitation in this
study. There were only five research articles investigating
the interaction between the infection with HPV and p53
codon 72 polymorphism on the risk of oral carcinoma.
Thus, additional studies with larger sample size are
needed to further evaluate the impact of HPV infection
and p53 Arg72Pro polymorphism on HPV-associated
oral cancer susceptibility.
Conclusion
For the first time, the current study provided the quanti-
tatively synthesized estimates for the effect of interaction
between HPV infection and p53 Arg72Pro polymorph-
ism on the risk of developing oral cancer. This combined
effect might together alter an individual’s susceptibility
to oral cancer. Our results suggested that p53 Arg72Pro
polymorphism may partly contribute to the pathogenesis
of oral cancer development. Further well-designed stud-
ies with reference to the interactions of gene-gene and
gene-environment on p53 codon 72 polymorphism to
oral carcinoma susceptibility are required.
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